• About us
• Contact

Advertisement

Organisation › Details

Cytosurge AG

Cytosurge, a Swiss-based global leader in precision single cell manipulation, was founded in 2009 by scientists at the Swiss Federal Institute of Technology (ETH Zurich). Besides developing, manufacturing, and distributing state-of-the-art systems for single cell research, Cytosurge now also offers a service for engineered cell lines based on its patented FluidFM® technology. FluidFM® technology enables gentle and direct cell manipulation such as direct intra-nuclear delivery of CRISPR RNP and therefore is especially suited for sensitive cells and complex edits. Worldwide, more than 100 laboratories are already using FluidFM® solutions, pushing conventional technological boundaries in CRISPR cell line development, mechanobiology, virology, single cell omics, neuroscience, and nanoprinting. *

 

	Start	2009-01-01 established
	Predecessor	ETH Zürich (ETHZ)
	Industry	cell analysis technology
	Industry 2	FluidFM® technology
	Person	Behr, Pascal (Cytosurge 201806 CEO)
	Person 2	Serre, Alexander (Cytosurge 201802 Sales + Marketing Director)
	Region	Glattbrugg ZH
	Country	Switzerland
	Street	25 Sägereistr.
	City	8152 Glattbrugg ZH
	Tel	+41-43-544-8700
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Cytosurge AG. (3/30/22). "Press Release: Cytosurge Launches Cell Line Engineering Services Based on Proprietary FluidFM Technology". Zurich.
		Record changed: 2023-07-10

Advertisement

More documents for Cytosurge AG

• [1] Cytosurge AG. (3/30/22). "Press Release: Cytosurge Launches Cell Line Engineering Services Based on Proprietary FluidFM Technology". Zurich....
• [2] Cytosurge AG. (1/18/22). "Press Release: R&D Project by Cytosurge and the Laboratory of Biosensors and Bioelectronics at the Swiss Federal Institute of Technology Receives Funding by Innosuisse". Zurich....
• [3] Cytosurge AG. (3/24/21). "Press Release: Cytosurge’s FluidFM Technology Facilitates Multiplex CRISPR Editing and Monoclonal Cell Line Development in less than Three Weeks". Zürich....
• [4] Cytosurge AG. (8/26/20). "Press Release: Cytosurge Announces Appointment of Thomas Bachmann to Board of Directors". Zurich....
• [5] Cytosurge AG. (8/21/19). "Press Release: Cytosurge AG Announces Spin-off of Its 3D Printing Business Unit". Glattbrugg....
• [6] Cytosurge AG. (7/9/19). "Press Release: Olympus Europe and Cytosurge Partner to Enhance Pharma Drug Development and Single Cell Research". Zurich / Glattbrugg & Hamburg....
• [7] Cytosurge AG. (6/29/18). "Press Release: Partnership between Bruker and Cytosurge – Enabling FluidFM Single Cell Experiments on the BioScope Resolve BioAFM". Zurich / Glattbrugg....
• [8] Bruker Corporation. (6/27/18). "Press Release: Bruker Introduces FluidFM on the BioScope Resolve BioAFM". Santa Barbara, CA....
• [9] Lab Automation Network (LAN). (2/1/18). "Press Release: Cytosurge AG and Lab Automation Network Announce Partnership for Automated Single-cell Biology Applications"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.